With advances in immunosuppressive therapy, there have been significant improvements in
acute rejection rates and short‐term allograft survival in kidney transplant recipients …

Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ
transplant survival. However, these drugs are characterized by a restricted therapeutic …

Aims The aims of this study were to describe the pharmacokinetics of tacrolimus immediately
after kidney transplantation, and to develop a clinical tool for selecting the best starting dose …

Background Following solid organ transplantation, tacrolimus (TAC) is an essential drug in
the immunosuppressive strategy. Its use constitutes a challenge due to its narrow …

Cytochromes from the P450 family (CYP) play a central role in the primary metabolism of
frequently prescribed antidepressants, potentially affecting their efficacy and tolerance …

Tacrolimus is the cornerstone of immunosuppressive therapy after kidney transplantation
(KT), but its use is complicated by a narrow therapeutic index and high inter-and intra-patient …

The immunosuppressant tacrolimus (TAC) is metabolized by both cytochrome P450 3A4
(CYP3A4) and CYP3A5 enzymes. It is common for European Americans (EA) to carry two …

Tacrolimus trough and dose requirements vary dramatically between individuals of
European and African American ancestry. These differences are less well described in other …

For three decades, tacrolimus (Tac) dose adjustment in clinical practice has been calculated
empirically according to the manufacturer's labeling based on a patient's body weight. Here …

Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the
liver, responsible for the oxidative metabolism of∼ 50% of clinically prescribed drugs …